Sofinnova Partners, the veteran French early-stage venture capital firm, has led the first round of financing for CareX and Faust Pharmaceuticals, two French biopharmaceutical firms, affirming its commitment to seed stage financing and support of young French technology companies.

CareX has raised a total of €6m ($5.3m). Sofinnova has invested €3.3m, Belgian venture capital fund Gimv €2m, and a third investor, new Belgian and US fund Mara Ventures, also joined the financing round.